Literature DB >> 29353090

Investigating the prevalence of febrile convulsion in Kayseri, Turkey: An assessment of the risk factors for recurrence of febrile convulsion and for development of epilepsy.

Mehmet Canpolat1, Huseyin Per2, Hakan Gumus3, Ferhan Elmali4, Sefer Kumandas5.   

Abstract

PURPOSE: The purpose of this study was to investigate the prevalence and recurrence of febrile convulsion (FC) and risk factors for development of epilepsy in school children throughout in the Kayseri provincial center.
METHOD: Ten thousand individuals selected using "stratified cluster sampling" from a student population of 259,428 inside the Kayseri Urban Municipality represented the study sample. Fifteen thousand questionnaires were distributed, of which 10,742 (71.6%) were returned. Telephone interviews were performed with the families of the students reported as having undergone FC, and the medical records of patients with a history of hospitalization were evaluated. Data were analyzed on IBM SPSS Statistics 22.0 package program. Significance was set at p < 0.05.
RESULTS: Prevalence of FC was 4.2% in girls and 4.3% in boys, with a total prevalence of 4.3%. Recurrence of FC was observed in 25.4% of cases. Risk of recurrence increased 7.1 times in subjects with a history of FC in first and second degree relatives, 17.8 times in those with fever interval <1 h before convulsion and 17.6 times in those with pre-convulsion body temperature <39 °C. Epilepsy developed in 33 (7.2%) cases. Neurodevelopmental abnormality was the most important risk factor for epilepsy (21.1-fold risk increase).
CONCLUSIONS: Analysis revealed that FC with a good prognosis had a high rate of recurrence and a higher risk of epilepsy than in the general population. The prevalence of FC in the province of Kayseri was closer to that in developed rather than developing countries.
Copyright © 2018 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Child; Epilepsy; Febrile convulsions; Kayseri; Prevalence; Risk factors

Mesh:

Year:  2018        PMID: 29353090     DOI: 10.1016/j.seizure.2018.01.007

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  7 in total

1.  Snotwatch: an ecological analysis of the relationship between febrile seizures and respiratory virus activity.

Authors:  Rana Sawires; Martin Kuldorff; Michael Fahey; Hazel Clothier; Jim Buttery
Journal:  BMC Pediatr       Date:  2022-06-22       Impact factor: 2.567

2.  The baseline risk of multiple febrile seizures in the same febrile illness: a meta-analysis.

Authors:  Christopher Henry; Chelsea Cockburn; Mary Helen Simpson; Serenity Budd; Chen Wang; Darina Dinov
Journal:  Eur J Pediatr       Date:  2022-03-16       Impact factor: 3.860

3.  Anthropogenetic Variability in the Group of Individuals with Febrile Seizures: Population-Genetic Study.

Authors:  Sanja Dimitrijevic; Suzana Cvjeticanin; Aleksandra Pusica; Biljana Jekic; Tamara Filipovic; Dimitrije Nikolic
Journal:  Biomed Res Int       Date:  2018-07-05       Impact factor: 3.411

Review 4.  A Review of Febrile Seizures: Recent Advances in Understanding of Febrile Seizure Pathophysiology and Commonly Implicated Viral Triggers.

Authors:  Rana Sawires; Jim Buttery; Michael Fahey
Journal:  Front Pediatr       Date:  2022-01-13       Impact factor: 3.418

5.  Increased Frequency of Febrile Seizures in Two Periodic Fever Syndromes: Familial Mediterranean Fever and PFAPA Syndrome.

Authors:  Hüseyin Kılıç; Aybüke Gurup Özen; Kenan Barut; Esra Pehlivan; Sezgin Şahin; Amra Adrovic; Özgür Kasapçopur; Sema Saltik
Journal:  Turk Arch Pediatr       Date:  2022-07

Review 6.  Febrile seizures: an overview.

Authors:  Alexander Kc Leung; Kam Lun Hon; Theresa Nh Leung
Journal:  Drugs Context       Date:  2018-07-16

7.  Seizure prevalence in children aged up to 3 years: a longitudinal population-based cohort study in Japan.

Authors:  Masahiro Nishiyama; Hiroshi Yamaguchi; Yusuke Ishida; Kazumi Tomioka; Hiroki Takeda; Noriyuki Nishimura; Kandai Nozu; Hiroki Mishina; Kazumoto Iijima; Hiroaki Nagase
Journal:  BMJ Open       Date:  2020-09-10       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.